HC Wainwright & Co. Maintains Buy on Enliven Therapeutics, Raises Price Target to $73

HC Wainwright & Co. analyst Robert Burns has maintained a 'Buy' rating on Enliven Therapeutics (NASDAQ: ELVN) and increased the price target from $65 to $73. This adjustment reflects a positive outlook for the company's performance in the market.